Altamira Therapeutics Files 6-K Report
Ticker: CYTOF · Form: 6-K · Filed: Aug 29, 2025 · CIK: 1601936
Sentiment: neutral
Topics: 6-K, foreign-private-issuer, regulatory-filing
TL;DR
Altamira Therapeutics (formerly Auris Medical) filed its 6-K for Q2 2025, standard foreign issuer report.
AI Summary
Altamira Therapeutics Ltd. filed a Form 6-K on August 29, 2025, reporting for the period ending June 30, 2025. The company, formerly known as Auris Medical Holding Ltd., is incorporated in Bermuda and operates in the pharmaceutical preparations sector. This filing is a report of a foreign private issuer.
Why It Matters
This filing provides updated information for investors and regulators regarding Altamira Therapeutics' operations as a foreign private issuer.
Risk Assessment
Risk Level: low — A 6-K filing is a routine report for foreign private issuers and typically does not contain material non-public information that would significantly alter risk.
Key Players & Entities
- Altamira Therapeutics Ltd. (company) — Registrant
- Auris Medical Holding Ltd. (company) — Former company name
- 001-36582 (company) — SEC File Number
- 20250829 (date) — Filing date
- 20250630 (date) — Reporting period end date
FAQ
What is the primary purpose of this Form 6-K filing?
The Form 6-K is a Report of Foreign Private Issuer filed pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, for the month of August 2025.
What was Altamira Therapeutics Ltd. formerly known as?
Altamira Therapeutics Ltd. was formerly known as Auris Medical Holding Ltd. and Auris Medical Holding AG.
What is the fiscal year end for Altamira Therapeutics Ltd.?
The fiscal year end for Altamira Therapeutics Ltd. is December 31 (1231).
Where is Altamira Therapeutics Ltd.'s principal executive office located?
The principal executive office is located at Clarendon House, 2 Church Street, Hamilton HM11, Bermuda.
Does Altamira Therapeutics Ltd. file annual reports under Form 20-F or Form 40-F?
Yes, Altamira Therapeutics Ltd. files annual reports under cover of Form 20-F.
Filing Stats: 380 words · 2 min read · ~1 pages · Grade level 11.9 · Accepted 2025-08-29 07:41:03
Filing Documents
- ea0254753-6k_altamira.htm (6-K) — 21KB
- ea025475301ex99-1_altamira.htm (EX-99.1) — 331KB
- ea025475301ex99-2_altamira.htm (EX-99.2) — 90KB
- ea025475301ex99-3_altamira.htm (EX-99.3) — 66KB
- ex99-3_001.jpg (GRAPHIC) — 3KB
- 0001213900-25-082071.txt ( ) — 2703KB
- cyto-20250630.xsd (EX-101.SCH) — 39KB
- cyto-20250630_cal.xml (EX-101.CAL) — 37KB
- cyto-20250630_def.xml (EX-101.DEF) — 147KB
- cyto-20250630_lab.xml (EX-101.LAB) — 301KB
- cyto-20250630_pre.xml (EX-101.PRE) — 161KB
- ea0254753-6k_altamira_htm.xml (XML) — 267KB
Management's Discussion and Analysis of Financial Condition and Results of Operations
Management's Discussion and Analysis of Financial Condition and Results of Operations 99.3 Press Release dated August 29, 2025 101.INS Inline XBRL Instance Document 101.SCH Inline XBRL Taxonomy Extension Schema Document 101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document 101.LAB Inline XBRL Taxonomy Extension Label Linkbase Document 101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document 101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document 104 Cover Page Interactive Data File formatted as Inline XBRL and contained in Exhibit 101 3